DOCSLIB.ORG

Low Expression of PTK6/Brk Predicts Poor Prognosis in Patients With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Low Expression of PTK6/Brk Predicts Poor Prognosis in Patients With Liu et al. Journal of Translational Medicine 2013, 11:59 http://www.translational-medicine.com/content/11/1/59 RESEARCH Open Access Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma Xue-Kui Liu1,2†, Xin-Rui Zhang1,2†, Qian Zhong1,3, Man-Zhi Li1,3, Zhi-Min Liu1,2, Zhi-Rui Lin1,3,DiWu1,2 and Mu-Sheng Zeng1,3,4* Abstract Background: Protein tyrosine kinase 6 (PTK6), also known as breast tumor kinase (Brk), was a nonreceptor tyrosine kinase containing SH3, SH2, and tyrosine kinase catalytic domains. The deregulated expression of PTK6 was observed in various human cancers. However, little was known about PTK6 expression and its clinicopathological significance in human laryngeal squamous cell carcinoma (LSCC). Materials: PTK6 expression was evaluated in 7 pairs of surgically resectable laryngeal tissues by Western blotting and in 13 pairs of surgically resectable laryngeal tissues by reverse transcription-PCR (RT-PCR). Using immunohistochemistry, we performed a retrospective study of the PTK6 expression levels on 134 archival LSCC paraffin-embedded samples. Prognostic outcomes correlated with PTK6 were examined using Kaplan–Meier analysis and Cox proportional hazards model. Results: The PTK6 expression level was lower in LSCC tissues than in the adjacent noncancerous epithelial laryngeal tissues by Western blots and RT-PCR. By immunohistochemical analysis, we observed high expression of PTK6 in 25 of 76 (32.9%) adjacent noncancerous epithelial laryngeal tissues and in 39 of 134 (29.1%) of LSCC, respectively. Multivariate analysis demonstrated that pN status and the expression level of PTK6 (P < 0.05) were independent and significant prognostic factors. In the primary LSCC category, median DFS (disease free survival) of high, medium and low PTK6 expression patients were 88.5 months ,74.5 months and 49.0 months (log-rank test, P = 0.002); median OS (overall survival) of high, medium and low PTK6 expression patients were 88.5 months ,76.3 months and 65.7 months (log-rank test, P = 0.002). Reduced cytoplasmic PTK6 expression in LSCC was significantly associated with late pN status (P =0.005, r = 0.27), advanced pTNM stages (III and IV) (P =0.027, r = 0.147), and poor differentiated LSCC (P <0.0001, r = 0.486). In adjacent paracancerous laryngeal epithelial samples, median DFS of high, medium and low PTK6 expression patients were 92.6 months ,75.6 months and 48.5 months (log-rank test, P = 0.020); median OS of high, medium and low PTK6 expression patients were 92.9 months ,78.9 months and 74.6 months (log-rank test, P = 0.042). Conclusion: The present findings indicated that cytoplasmic PTK6 expression is a potential prognostic factor for survival in LSCC patients. High expression of PTK6 was associated with favorable OS and DFS in LSCC patients. Keywords: PTK6/Brk, Laryngeal squamous cell carcinoma, Prognosis * Correspondence: [email protected] †Equal contributors 1State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, China 3Department of Experimental Research, Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, China Full list of author information is available at the end of the article © 2013 liu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Liu et al. Journal of Translational Medicine 2013, 11:59 Page 2 of 9 http://www.translational-medicine.com/content/11/1/59 Background (MRI), bilateral cervical and supraclavicular ultrasonog- The cytoplasmic non-receptor tyrosine kinase PTK6 raphy, and abdominal ultrasonography. The medical re- (BRK, breast tumour kinase) was originally cloned from a cords of these patients were reviewed to assess the human metastatic breast tumour [1]. The 53 kDa PTK6 patients’ characteristics, including age, sex, primary site, protein was a cytoplasmic tyrosine kinase, and structurally clinical stage, date of disease progression, and final sta- resembled tyrosine kinases of the Src family [2]. Src family tus on the last follow-up examination. The informed tyrosine kinases play important roles in epithelial tumor consent was obtained from each patient prior to surgery development. Therefore, it was proposed that PTK6 may and the study was approved from the Institute Research play a role in epithelial tumorigenesis [3,4]. Ethics Committee. The overexpression of tyrosine kinases (including EphA1, PTK6/BRK, and Ron) were reported in head and Western blot neck cancers which included pharyngeal, hypopharyngeal, Western blotting analysis was carried out with the pro- tonsilar, supraglottic and some oral cancers [5]. However, teins collected from the adjacent normal epithelium tis- PTK6 expression in tumor tissues was complex. For ex- sues and the cancer tissues, and total proteins were ample, PTK6 was localized in the nucleus and cytoplasm extracted with 1 X sodium dodecyl sulfate (SDS) sample of normal oral epithelium, and in perinuclear regions of buffer (2% SDS, 62.5 mmol/L Tris–HCl (pH 6.8), 5% 2- poorly differentiated oral squamous carcinomas [3]. PTK6 mercaptoethanol, and 10% glycerol) . The concentration expression was low or undetectable in normal ovary [2] or of the protein was measured by the BCA protein assay normal breast epithelium [3,4,6], but it was found in hu- kit (PIERCE, Rockford, IL, USA). A total of 20 μg pro- man ovarian tumor cells [2] and in greater than 60% of tein was electrophoretically separated in 12% SDS poly- breast tumors and breast cancer derived cell lines [7], indi- acrylamide gels and transferred onto polyvinylidene cating that overexpression of PTK6 may be related to car- difluoride membranes (Amersham Pharmacia Biotech, cinogenesis. Aubele et al. [6] reported that PTK6 protein Piscataway, NJ). Then incubate the primary polyclonal expression had prognostic value in a small set of 105 antibody against PTK6 (dilution, 1:1000; Abgent INC, breast carcinomas. However, the expression of PTK6 and USA),which was mixed with PTK6 Antibody (N-term) its clinical significance were not clearly documented in Blocking Peptide (0.25 ug/ml ), in 5% of the skimmed LSCC. In the current study, we aimed to investigate PTK6 milk solution overnight at 4°C, and anti-rabbit (1:3000; expression and analyze its association with clinicopatho- Santa Cruz Biotechnology, Santa Cruz, CA) secondary logical factors to understand its potential role in LSCC. antibody was were used to detect PTK6 protein. Anti- glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Material and method (1:4000, Santa Cruz, CA, USA) antibody and anti-mouse Tissue samples and patients (1:4000; Santa Cruz Biotechnology, Santa Cruz, CA) sec- Fresh tumor tissue samples with paired non-cancerous ondary antibody were used to confirm equal loading. normal mucosa (with more than a 5-mm distance from The protein signals were detected by the enhanced the primary tumor’s edge) of 13 LSCC patients were chemiluminescence (ECL) detection system (Amersham obtained at the time of operation from the Sun Yat-sen Biosciences Europe, Freiburg, Germany) according to University Cancer Center (SYSUCC). All the 13 patients the manufacturer's protocols. were histologically confirmed as LSCC by biopsy pre- operation and all these patients underwent total laryn- Real time reverse transcription-polymerase chain reaction gectomy in the primary site. Before making extraction, (RT-PCR) analysis we did frozen section and made sure that all the speci- Total RNAs from fresh tissues were purified from tissues mens were done on at least 70%-80% tumor cells under using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) the microscope. A total of 134 patients who were previ- according to the manufacturer’s instructions, and 2 μg ously untreated and histologically confirmed LSCC, in RNA of each sample was reverse transcribed using resectable stages (T1~4aN0-3 M0 ) (Union for Inter- SuperScript RT kit (Invitrogen Life Technologies, Carls- national Cancer Control ,UICC 2002) were eligible be- bad, CA, USA). Full-length open reading frame of PTK6 tween January 2003 and December 2005 at SYSUCC in was amplified by PCR from cDNA samples of normal la- our study. Patients who had previous malignant disease, ryngeal epithelium tissues and laryngeal carcinoma tis- a second primary tumor, positive margin, or died of sues. Real-time PCR was carried out using a CFX96 postoperative complications were excluded. Pretreat- Real-Time System (BIO-RAD) (PREMIER Biosoft ment evaluations included a complete history, physical International, Palo Alto CA, USA). Sequences of the examination, performance status, serum chemistry pro- primers were as follows: PTK6, 5’-TACTTTGGGGA file, complete blood cell count, chest radiography, com- GGT CTTCGAG-3’(sense), 5’-TGCCGCAGCTTCTTC puted tomography (CT) or magnetic resonance imaging ATG-3’(antisense);GAPDH, 5'-GACTCATGACCACAG Liu et al. Journal of Translational Medicine 2013, 11:59 Page 3 of 9 http://www.translational-medicine.com/content/11/1/59 TCCATGC-3' (sense), 5'-AGAGGCAGGGATGATGTT LSCC patients were divided into three groups (1–2, low CTG-3' (antisense). We used the SYBR Green kit (Invitrogen expression; 3–5, medium expression and 6–7, high Life Technologies, Carlsbad, CA, USA) to execute the PTK6 expressing). Each section was evaluated by two in- amplification of the cDNA. The RT-PCR cycling pa- dependent pathologists without knowledge of the clinical rameters were performed as follows: denaturation at features of the cases. 95°C for 15 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds. The expression Statistical analysis data were normalized to the geometric mean of house- The paired T-test was used to analyze the significance of keeping gene GAPDH to control the difference in ex- PTK6 protein levels and mRNA levels in the paired sam- pression levels and analyzed using the 2-Delta Delta C ples.
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells
    Published OnlineFirst January 30, 2013; DOI: 10.1158/1541-7786.MCR-12-0378 Molecular Cancer Oncogenes and Tumor Suppressors Research Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells Natalie Ludyga1, Natasa Anastasov2, Michael Rosemann2, Jana Seiler1, Nadine Lohmann1, Herbert Braselmann3, Karin Mengele4, Manfred Schmitt4, Heinz Ho€fler1,5, and Michaela Aubele1 Abstract Breast cancer is the most common malignancy in women of the Western world. One prominent feature of breast cancer is the co- and overexpression of HER2 and protein tyrosine kinase 6 (PTK6). According to the current clinical cancer therapy guidelines, HER2-overexpressing tumors are routinely treated with trastuzumab, a humanized monoclonal antibody targeting HER2. Approximately, 30% of HER2-overexpressing breast tumors at least initially respond to the anti-HER2 therapy, but a subgroup of these tumors develops resistance shortly after the administration of trastuzumab. A PTK6-targeted therapy does not yet exist. Here, we show for the first time that the simultaneous knockdown in vitro, compared with the single knockdown of HER2 and PTK6, in particular in the trastuzumab-resistant JIMT-1 cells, leads to a significantly decreased phosphorylation of crucial signaling proteins: mitogen-activated protein kinase 1/3 (MAPK 1/3, ERK 1/2) and p38 MAPK, and (phosphatase and tensin homologue deleted on chromosome ten) PTEN that are involved in tumorigenesis. In addition, dual knockdown strongly reduced the migration and invasion of the JIMT-1 cells. Moreover, the downregulation of HER2 and PTK6 led to an induction of p27, and the dual knockdown significantly diminished cell proliferation in JIMT-1 and T47D cells.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Structure, Function, and Regulation of the SRMS Tyrosine Kinase
    International Journal of Molecular Sciences Review Structure, Function, and Regulation of the SRMS Tyrosine Kinase Chakia J. McClendon 1 and W. Todd Miller 1,2,* 1 Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY 11794-8661, USA; [email protected] 2 Department of Veterans Affairs Medical Center, Northport, NY 11768, USA * Correspondence: [email protected] Received: 21 May 2020; Accepted: 12 June 2020; Published: 14 June 2020 Abstract: Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristoylation sites (SRMS) is a tyrosine kinase that was discovered in 1994. It is a member of a family of nonreceptor tyrosine kinases that also includes Brk (PTK6) and Frk. Compared with other tyrosine kinases, there is relatively little information about the structure, function, and regulation of SRMS. In this review, we summarize the current state of knowledge regarding SRMS, including recent results aimed at identifying downstream signaling partners. We also present a structural model for the enzyme and discuss the potential involvement of SRMS in cancer cell signaling. Keywords: tyrosine kinase; signal transduction; phosphorylation; SH3 domains; SH2 domains; Src family kinases 1. Introduction Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristoylation sites (SRMS) is a 53 kDa nonreceptor tyrosine kinase that was first discovered in mouse neural precursor cells [1]. Studies of the expression pattern of SRMS mRNA showed that the highest levels were present in lung, testes, and liver tissues. Full-length cDNA encoding SRMS was isolated from a murine lung cDNA library, with the predicted SRMS protein containing all of the conserved amino acid residues expected for a nonreceptor tyrosine kinase.
    [Show full text]
  • Amanda Harvey Institute for Environment Health and Societies
    PROTEIN TYROSINE KINASE-6 (PTK6) Amanda Harvey Institute for Environment Health and Societies Brunel University London United Kingdom [email protected] Synonyms Breast Tumor Kinase (Brk) Historical Background The intracellular protein tyrosine kinase, PTK6 (also known as the breast tumor kinase, Brk), has been implicated in the development and progression of a number of different tumor types. First identified in 3 separate studies in the early 1990s, it was initially found in a study to determine which tyrosine kinases were expressed in human melanocytes and then the full-length sequence was subsequently cloned from metastatic breast cancer using a screen to identify novel kinases that were expressed in tumors, but not normal breast tissue. Identification of the murine orthologue, sik, in mouse intestinal cells was achieved by the generation of a library of kinase catalytic domains. PTK6 is related to the Src family of protein kinases and belongs to a distinct class of enzymes which includes Frk and SRMS (reviewed Harvey and Burmi 2011) and expression produces two different isoforms as a result of alternative splicing (reviewed in Hussain and Harvey 2014) (Figure 1). Figure 1 –– PTK6 Figure 1.tif Figure 1: PTK6 domain structure. Schematic representation of the PTK6 gene structure and its products. All 8 exons are contained in the PTK6 transcript, resulting in production of a full length, fully functional protein. ALT-PTK6 arises as a result of alternative splicing, excluding exon 2. The subsequent protein shares the amino-terminus and the SH3 domain with its full length isoform and a frameshift results in the carboxy-terminus being truncated and proline rich (PR) Under normal physiological conditions, PTK6 expression is highly controlled and is usually limited to differentiating cells of epithelial origin.
    [Show full text]
  • Effects of Fyn-Related-Kinase Activity on Breast
    EFFECTS OF FYN-RELATED-KINASE ACTIVITY ON BREAST CANCER CELL PROLIFERATION, MIGRATION, INVASION AND COLONY FORMATION A Thesis Submitted to the College of Graduate Studies and Research In Partial Fulfillment of the Requirements For the Degree of Master of Science In the Department of Biochemistry University of Saskatchewan Saskatoon By Chenlu Dai Copyright Chenlu Dai, January, 2015. All rights reserved. Permission to Use In presenting this thesis in partial fulfilment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was completed. It is understood that any copying or publication or use of this thesis or parts thereof financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to: Head of the Department of Biochemistry University of Saskatchewan Saskatoon, Saskatchewan, S7N 5E5 i ABSTRACT The human Fyn-related kinase (FRK) is a member of subfamily of Src-related kinases family.
    [Show full text]
  • Mammary Gland Specific Expression of Brk/PTK6 Promotes Delayed
    Lofgren et al. Breast Cancer Research 2011, 13:R89 http://breast-cancer-research.com/content/13/5/R89 RESEARCHARTICLE Open Access Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK Kristopher A Lofgren1,2,3, Julie H Ostrander1,3, Daniel Housa1,3,4, Gregory K Hubbard1,3, Alessia Locatelli1,3, Robin L Bliss3, Kathryn L Schwertfeger2,3,5 and Carol A Lange1,2,3,6* Abstract Introduction: Protein tyrosine kinases (PTKs) are frequently overexpressed and/or activated in human malignancies, and regulate cancer cell proliferation, cellular survival, and migration. As such, they have become promising molecular targets for new therapies. The non-receptor PTK termed breast tumor kinase (Brk/PTK6) is overexpressed in approximately 86% of human breast tumors. The role of Brk in breast pathology is unclear. Methods: We expressed a WAP-driven Brk/PTK6 transgene in FVB/n mice, and analyzed mammary glands from wild-type (wt) and transgenic mice after forced weaning. Western blotting and immunohistochemistry (IHC) studies were conducted to visualize markers of mammary gland involution, cell proliferation and apoptosis, as well as Brk, STAT3, and activated p38 mitogen-activated protein kinase (MAPK) in mammary tissues and tumors from WAP-Brk mice. Human (HMEC) or mouse (HC11) mammary epithelial cells were stably or transiently transfected with Brk cDNA to assay p38 MAPK signaling and cell survival in suspension or in response to chemotherapeutic agents. Results: Brk-transgenic dams exhibited delayed mammary gland involution and aged mice developed infrequent tumors with reduced latency relative to wt mice.
    [Show full text]
  • Dasatinib Response in Acute Myeloid Leukemia Is Correlated with FLT3 /ITD, PTPN11 Mutations and a Unique Gene Expression Signature
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Dasatinib response in acute myeloid leukemia is correlated with FLT3 /ITD, PTPN11 mutations and a unique gene expression signature Sigal Tavor, 1 Tali Shalit, 2 Noa Chapal Ilani, 3 Yoni Moskovitz, 3 Nir Livnat, 3 Yoram Groner, 4 Haim Barr, 2 Mark D. Minden, 5,6,7,8 Alexander Plotnikov, 2 Michael W. Deininger, 9,10 Nathali Kaushansky 3,# and Liran I. Shlush 3,5,11,# 1Hemato-Oncology Department, Assuta Medical Center, Tel Aviv, Israel; 2G-INCPM, Weizmann Institute of Science, Rehovot, Israel; 3De - partment of Immunology, Weizmann Institute of Science, Rehovot, Israel; 4Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel; 5Princess Margaret Cancer Centre, University Health Network Toronto, Ontario, Canada; 6Department of Med - ical Biophysics, University of Toronto, Toronto, Ontario, Canada; 7Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 8Division of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada; 9Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA; 10 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA and 11 Division of Hematology, Rambam Healthcare Campus, Haifa, Israel #NK and LIS contributed equally as co-senior authors. ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.240705 Received: October 16, 2019 Accepted: April 30, 2020. Pre-published: May 21, 2020. Correspondence: LIRAN I. SHLUSH - [email protected] Supplementary Methods Drugs library The 46 drugs cover a broad range of pathways and mechanisms of action. A large group of drugs which we tested are FLT3 targeted tyrosine kinase inhibitors, a common mutation with adverse prognosis in AML.
    [Show full text]
  • Signal Transducer and Activator of Transcription 5B: a New Target of Breast Tumor Kinase/Protein Tyrosine Kinase 6 Amanda M Weaver1,3 and Corinne M Silva1,2,3
    Available online http://breast-cancer-research.com/content/9/6/R79 ResearchVol 9 No 6 article Open Access Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6 Amanda M Weaver1,3 and Corinne M Silva1,2,3 1Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA 2Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA 3Cancer Center, University of Virginia, Charlottesville, VA 22908, USA Corresponding author: Corinne M Silva, [email protected] Received: 25 Jul 2007 Revisions requested: 23 Aug 2007 Revisions received: 21 Sep 2007 Accepted: 12 Nov 2007 Published: 12 Nov 2007 Breast Cancer Research 2007, 9:R79 (doi:10.1186/bcr1794) This article is online at: http://breast-cancer-research.com/content/9/6/R79 © 2007 Weaver and Silva; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction Signal transducers and activators of transcription STAT5b phosphorylation at the activating tyrosine, Y699. (STATs) are mediators of cytokine and growth factor signaling. Transient transfection of Brk into the Brk-negative BT-549 In recent years, STAT5b has emerged as a key regulator of breast cancer cell line enhanced STAT5b transcriptional activity, tumorigenesis. STAT5b phosphorylation and activation is as measured by a STAT5-specific luciferase reporter. mediated by several kinases known to be overexpressed in Furthermore, overexpression of kinase active c-Src enhanced breast cancer, such as epidermal growth factor receptor, HER2, Brk-induced STAT5b transcriptional activity.
    [Show full text]
  • CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer
    Author Manuscript Published OnlineFirst on February 10, 2015; DOI: 10.1158/0008-5472.CAN-14-2443 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: CLK2 is an oncogenic kinase and splicing regulator in breast cancer Authors: Taku Yoshida1,2,3,13, Jee Hyun Kim1,2,3,4, Kristopher Carver1,2,3,14, Ying Su1,2,3, Stanislawa Weremowicz5,6, Laura Mulvey1,15, Shoji Yamamoto1,2,16, Cameron Brennan7, Shenglin Mei8,9, Henry Long8, Jun Yao1,2,3,10, Kornelia Polyak1,2,3,7,11,12 Authors’ Affiliations: 1Department of Medical Oncology, and 8Center for Functional Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Department of 2Medicine and 4Pathology, Harvard Medical School, Boston, Massachusetts, USA. Department of 3Medicine and 5Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 4Seoul National University College of Medicine, Seoul, Korea. 7Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 9Department of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, China. 10MD Anderson Cancer Center, Houston, TX. 11Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. 12Broad Institute, Cambridge, Massachusetts, USA. 13Present address: Eisai Co., Ltd., Tokyo, Japan. 14Present address: Boston Scientific, St. Paul, MN 55112, USA 15Present address: Maimonides Medical Center, Brooklyn, NY 11219, USA 16Present address: Daiichi Sankyo Co., Ltd., Tokyo, Japan Running Title: CLK2 as a therapeutic target in breast cancer Keywords: breast cancer, splicing, epithelial to mesenchymal transition List of abbreviations: SNP – Single Nucleotide Polymorphism, FISH – fluorescence in situ hybridization, BAC – bacterial artificial chromosome, CEP – centromeric probe, TNBC – Triple Negative Breast Cancer Notes: Financial support: This work was supported by the Susan G.
    [Show full text]
  • Modeling Brk/PTK6 Expression in the Mammary Epithelium
    Modeling Brk/PTK6 Expression in the Mammary Epithelium A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Kristopher Andrew Lofgren IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Adviser: Carol A. Lange December 2010 © Kristopher A. Lofgren, 2010 ACKNOWLEDGEMENTS I would like to gratefully acknowledge the following people: Dr. Carol Lange for her guidance in multiple facets of science and life. Lange Lab past and present (particularly Grey Hubbard, Dr. Daniel Housa, and Dr. Julie Ostrander, for direct technical contributions). Dr. Kaylee Schwertfeger for equipment use, temporary lab space, reagents and input. Funding for this work was provided by NIH/NCI R01 CA107547 to Carol A. Lange and a Department of Defense Breast Cancer Research Pre-doctoral Fellowship W81XWH-06- 1-0752 to Kristopher A. Lofgren i DEDICATION I would like to dedicate my dissertation to my entire family and wife. Thank you for all of your support and inspiration through the years. ii ABSTRACT Protein tyrosine kinases (PTKs) regulate cellular proliferation and differentiation during development and homeostasis of normal tissues. Additionally, PTKs are frequently overexpressed in cancers. As such, they have become promising targets for new therapies. Breast tumor kinase (Brk/PTK6) is a non-receptor tyrosine kinase initially cloned from a metastatic breast tumor, and is overexpressed in ~86% of human breast tumors and several breast cancer cell lines. While expressed in differentiating cells in the skin and intestine, Brk is notably absent from normal mammary tissue and non- transformed mammary epithelial cell lines. The role of Brk/PTK6 in breast pathology is unclear.
    [Show full text]